The pooled HR for OS (Table 2) was 0.67, (95%CI, 0.62, 0.73; p < 0.001) without significant heterogeneity (I2 < 0.1%), which reflected that compared to non-PD-1/PD-L1 therapy, PD-1/PD-L1 blockades reduced 33% in risk of death among epithelial carcinoma patients. Here, CD274 is linked to carcinoma.